Who owns LB PHARMACEUTICALS INC?
- Ticker: LBRX
- CUSIP Number: 50180m108
Tip: Access positions for across all investors
Analyze quarterly positions in Lb Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Lb Pharmaceuticals stock
Who bought or sold LB PHARMACEUTICALS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Deep Track Capital | 3.4M | $83M | 0% | Mar 2026 |
|
| BlackRock | 2.5M | $61M | 10% | Mar 2026 |
|
| RA Capital Management | 2.2M | $55M | 0% | Mar 2026 |
|
| TCG Crossover Management | 1.8M | $45M | 5% | Mar 2026 |
|
| Commodore Capital | 1.5M | $37M | 0% | Mar 2026 |
|
| Trails Edge Capital Partners | 1.3M | $33M | 100% | Mar 2026 |
|
| Vanguard Group | 1.1M | $25M | 100% | Dec 2025 |
|
| Nantahala Capital Management | 1.1M | $26M | 56% | Mar 2026 |
|
| Balyasny Asset Management | 924k | $23M | 3% | Mar 2026 |
|
| Logos Global Management | 915k | $23M | -24% | Mar 2026 |
|
| Vanguard Capital Management | 895k | $22M | 100% | Mar 2026 |
|
| Alyeska Investment Group | 864k | $21M | 28% | Mar 2026 |
|
| Vivo Capital | 800k | $20M | 0% | Mar 2026 |
|
| Jennison Associates | 538k | $13M | -35% | Mar 2026 |
|
| Geode Capital Management | 518k | $13M | 17% | Mar 2026 |
|
| Citadel Advisors | 417k | $10M | 2% | Mar 2026 |
|
| Goldman Sachs Group | 364k | $9.0M | 20% | Mar 2026 |
|
| Dr. Jeffrey R. Jay, M.D. | 300k | $7.4M | 100% | Mar 2026 |
|
| Nan Fung Group Holdings | 300k | $6.7M | 0% | Dec 2025 |
|
| State Street Corporation | 250k | $5.6M | 100% | Dec 2025 |
|
| FMR | 222k | $4.9M | -40% | Dec 2025 |
|
| Baker Bros. Advisors | 200k | $4.9M | 0% | Mar 2026 |
|
| Charles Schwab Investment Management | 178k | $4.0M | 100% | Dec 2025 |
|
| Vanguard Fiduciary Trust | 157k | $3.9M | 100% | Mar 2026 |
|
| Northern Trust | 144k | $3.2M | 100% | Dec 2025 |
|
| HighVista Strategies | 140k | $3.1M | 100% | Dec 2025 |
|
| UBS Group | 138k | $3.4M | 172% | Mar 2026 |
|
| Millennium Management | 137k | $3.4M | 100% | Mar 2026 |
|
| Vanguard Portfolio Management | 113k | $2.8M | 100% | Mar 2026 |
|
| Ameriprise Financial | 108k | $2.7M | -44% | Mar 2026 |
|
| Integral Health Asset Management | 100k | $2.2M | 0% | Dec 2025 |
|
| Russell Investments | 72k | $1.8M | 4626% | Mar 2026 |
|
| Boxer Capital Management | 70k | $1.6M | 0% | Dec 2025 |
|
| Henderson Group | 65k | $1.6M | 100% | Mar 2026 |
|
| Stempoint Capital | 50k | $1.2M | 100% | Mar 2026 |
|
| Morgan Stanley | 47k | $1.2M | 100% | Mar 2026 |
|
| Bank of New York Mellon | 46k | $1.1M | 12% | Mar 2026 |
|
| Barclays | 30k | $673k | -2% | Dec 2025 |
|
| Longwood Capital Partners | 29k | $713k | -4% | Mar 2026 |
|
| Calamos Advisors | 24k | $593k | 100% | Mar 2026 |
|
| Nuveen | 23k | $566k | 0% | Mar 2026 |
|
| Colony | 20k | $447k | 100% | Dec 2025 |
|
| XTX Topco | 19k | $426k | 70% | Dec 2025 |
|
| Marshall Wace | 18k | $401k | -93% | Dec 2025 |
|
| Rhumbline Advisers | 17k | $422k | 5% | Mar 2026 |
|
| Bank of America Corporation | 17k | $410k | 100% | Mar 2026 |
|
| Deutsche Bank Aktiengesellschaft | 15k | $379k | 15% | Mar 2026 |
|
| Meyer Handelman | 15k | $372k | 100% | Mar 2026 |
|
| Opaleye Management | 15k | $358k | 100% | Mar 2026 |
|
| Two Sigma Investments | 13k | $314k | 0% | Mar 2026 |
|
| MetLife Investment Advisors | 11k | $247k | 100% | Dec 2025 |
|
| Invesco | 11k | $265k | -2% | Mar 2026 |
|
| Soleus Capital Management | 10k | $247k | 0% | Mar 2026 |
|
| Mirae Asset Global Etfs Holdings | 9.2k | $226k | 2% | Mar 2026 |
|
| Vanguard Global Advisers | 8.8k | $216k | 100% | Mar 2026 |
|
| Wells Fargo & Company | 8.6k | $213k | -61% | Mar 2026 |
|
| New York State Common Retirement Fund | 6.1k | $150k | 100% | Mar 2026 |
|
| Police & Firemen's Retirement System of New Jersey | 6.0k | $149k | 37% | Mar 2026 |
|
| Citigroup | 5.6k | $137k | 100% | Mar 2026 |
|
| OTR - Nominee Name for The State Teachers Retirement Board of Ohio | 5.1k | $126k | 50% | Mar 2026 |
|
| Federated Investors | 5.0k | $123k | 0% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 4.1k | $100k | 1% | Mar 2026 |
|
| Legal & General Group | 1.7k | $43k | -8% | Mar 2026 |
|
| Summit Investment Advisors | 1.6k | $39k | 0% | Mar 2026 |
|
| Tower Research Capital | 1.4k | $30k | 100% | Dec 2025 |
|
| California State Teachers Retirement System | 1.0k | $26k | -12% | Mar 2026 |
|
| Sterling Capital Management | 368.00 | $9.1k | -38% | Mar 2026 |
|
| GAMMA Investing | 162.00 | $4.0k | 1057% | Mar 2026 |
|
| Pnc Financial Services | 145.00 | $3.6k | 100% | Mar 2026 |
|
| Massmutual Trust | 54.00 | $1.3k | 100% | Mar 2026 |
|
| CWM | 8.00 | $0 | 100% | Dec 2025 |
|
| EverSource Wealth Advisors | 1.00 | $25.000000 | 100% | Mar 2026 |
|
Who sold out of Lb Pharmaceuticals?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Jpmorgan Chase & Co | Sep 2025 | 1.0M | $16M |
| Wellington Management Company | Sep 2025 | 345k | $5.4M |
| Adage Capital Partners GP | Sep 2025 | 200k | $3.2M |
| Longbow Finance SA | Dec 2025 | 82k | $1.8M |
| Silverarc Capital Management | Sep 2025 | 70k | $1.1M |
| Jane Street | Dec 2025 | 32k | $706k |
| Norges Bank Investment Management | Dec 2025 | 20k | $445k |
| Oxford Asset Management | Sep 2025 | 18k | $281k |
| Leucadia National Corporation | Dec 2025 | 12k | $277k |
| SG Americas Securities | Dec 2025 | 6.4k | $143k |
| Persistent Asset Partners | Dec 2025 | 4.1k | $91k |
| Amalgamated Bank | Dec 2025 | 605.00 | $13k |
| Quarry | Sep 2025 | 11.00 | $174.000200 |